1 |
US Department of Health and Human Services Food and Drug Administration. Innovation or Stagnation. www.fda.gov/oc/initiatives/criticalpath/whitepaper.html
|
2 |
대한핵의학회 방사성의약품위원회. 방사성의약품 제조관리 지침서 발간 및 평가기준 설정 2006
|
3 |
Vanbrocklin HF. FDA requests community input on RDRC and the exploratory IND. www.snidd.org/newsletters/NewsletterSummer05.pdf
|
4 |
Suleiman OH, Fejka R. The Radioactive Drug Research Committee: A 2007 update.(abstract) J Nucl Med 2007;48:327
|
5 |
US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry, Investigators, and Reviewers Exploratory IND Studies. http://www.fda.gov/cder/guidance/7086fnl.htm
|
6 |
US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Product. www.fda.gov/CDER/GUIDANCE/phase1.pdf
|
7 |
European Medicines Agency (EMEA), Evaluation of Medicines for Human Use, 'Position Paper on Non-Clinical Safety Studies to Support Clinical Trials with a Single Microdose,' CPMP/SWP/2599/ 02Rev 1
|
8 |
Suleiman OH, Fejka R, Houn F, Walsh M. The radioactive drug research committee: Background and retrospective study of reported research data (1975-2004). J Nucl Med 2006;47:1220-6
|